NEWYORKBIO WELCOMES 2025 CLASS OF BOARD OF DIRECTORS
NewYorkBIO announced today its newly appointed 2025 class of Board of Directors, comprised of skilled leaders united in their shared commitment to advancing the development of New York’s life science industry statewide. The newly elected members join a Board of visionary leaders that play an instrumental role in guiding NewYorkBIO’s efforts to advance innovation of treatment and cures that improve health outcomes and quality of life for New Yorkers and patients around the world.
This year’s class is made up of a wide range of professionals from various companies advancing the growth of biosciences in New York:
- Martha Auster, Vertex
- Matthew Badalucco, Merck
- Annette Bakker, Children’s Tumor Foundation
- Hans Christinger, Modig
- Will Debarros, Marsh McLennan
- Seth Flaum, Wilson Sonsini
- Karen Heidelberger, Deerfield
- David Lechner, Avantor
- Linda Malek, Crowell & Moring
- Sharon Mates, IntraCellular
- Glennis Mehra, Biolabs@NYULangone
- Ron Newbold, Empire Discovery Institute
- Kimberly Williams, Bristol Myers Squibb
Martha Auster, Annette Bakker, Hans Christinger, Will Debarros, Karen Heidelberger, David Lechner, Linda Malek, Sharon Mates, and Ron Newbold were each reelected to serve for another three-year term.
“NewYorkBIO is thrilled to welcome strong leaders in their fields to its Board to undoubtedly bring their own experiences, insights, and networks to every interaction on behalf of the organization,” said Jennifer Hawks Bland, NewYorkBIO CEO. “As we look toward the priorities of the new administration, we are eager to work with our 28 Board members to continue supporting and advocating for our members and furthering our mission to drive innovation for the future of life sciences to ultimately enhance and improve patient outcomes.”
The Board of Directors were elected by the NewYorkBIO membership in recognition of their leadership in the life science community. Through their various roles, the Board aims to guide NewYorkBIO on their mission to strengthen the life sciences industry statewide and influence policy at a pivotal time of increased investment in healthcare research and innovation. The board also oversees NewYorkBIO’s efforts to convene and support bioscience companies, universities, research institutions, and other organizations that are committed to improving health outcomes throughout New York and worldwide.
About NewYorkBIO
As the leading advocate for the life science community in New York, NewYorkBIO brings together hundreds of New York’s bioscience companies, universities, research institutions, and others dedicated to advancing life science research and commercializing treatments and cures for patients. NewYorkBIO connects key voices and companies of all sizes with resources to initiate and support transformative change to impact patient outcomes. Learn more at https://www.newyorkbio.org/.
